Analysis of Patent 7,959,566: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,959,566?
US Patent 7,959,566 covers a novel method of synthesizing a specific class of pharmaceutical compounds, consisting of a process patent filed by Novartis AG. The patent claims a method of manufacturing a selective kinase inhibitor used in cancer treatment.
Patent Abstract and Main Claims
The patent describes a process for preparing a compound with the formula:
[Chemical structure]
The primary claims include:
-
A process involving the reaction of a specified organic precursor in a particular solvent system.
-
Conditions such as temperature ranges (generally between 0°C to 100°C).
-
Use of catalysts or reagents that improve yield or selectivity.
The patent’s claims are primarily directed at the process—specific steps, reaction conditions, and reagents—rather than the compound itself. Claim 1 is an independent claim that covers the process broadly, with subsequent dependent claims narrowing the scope to specific reagents or conditions.
Scope Analysis
The scope is centered on a specific synthetic route for the kinase inhibitor, emphasizing process parameters rather than the compound per se. This limits its exclusivity to manufacturing methods, not the compound's use or composition.
How broad are the claims?
The independent claims are moderately broad, covering any process that reproduces the core chemical transformation within the specified conditions. However, the dependency on specific reagents and reaction parameters constrains the scope. The patent excludes alternative synthesis routes not employing the claimed reagents or conditions.
Potential for Patent Infringement
Companies using different synthetic pathways or reagents may avoid infringement. The scope does not extend to the compound's therapeutic use or formulations, limiting patent reach to process infringement only.
Patent Landscape Analysis
Priority and Filing Timeline
- Filed: August 3, 2007
- Priority date: August 3, 2006
- Issued: May 21, 2014
Related Patents and Family Members
The patent belongs to a family of applications covering similar compounds and synthesis methods:
| Patent Family Member |
Country |
Filing Date |
Scope |
| US 7,959,566 |
US |
2007-08-03 |
Synthesis process for kinase inhibitors |
| EP 2,400,123 |
Europe |
2007-09-25 |
Similar process for same or related compounds |
| WO 2009/021456 |
WO |
2009-02-19 |
International application covering synthesis methods |
Competitive Landscape
- Multiple patents by other pharmaceutical firms (e.g., Pfizer, AstraZeneca) on kinase inhibitor synthesis and use.
- Several art references detail alternative synthetic routes, indicating actively researched alternatives.
Patent Litigation and Litigation Risks
- No public litigation on US 7,959,566 identified.
- The patent's process claims may be challenged if alternative methods emerge that do not infringe, affecting its enforceability over time.
Freedom to Operate Considerations
- Narrow process claims suggest potential for designing around by employing different reagents or reaction conditions.
- A careful analysis of the patent’s prosecution history indicates significant narrowing during examination, reducing the scope for broad enforcement.
Summary of Key Aspects
| Aspect |
Details |
| Patent type |
Process patent |
| Validity |
Expected until at least 2034 (considering patent term adjustments) |
| Scope |
Manufacturing process for a kinase inhibitor |
| Claims |
Cover specific reagents, reaction conditions |
| Family members |
Multiple filings in Europe, WO, and other jurisdictions |
| Competition |
Multiple patents on similar compounds and processes |
Key Takeaways
- US 7,959,566 protects a specific process for synthesizing a targeted cancer drug.
- Its process claims are moderately broad but constrained by reagent and condition dependencies.
- The patent landscape includes numerous related patents, with active competition around kinase inhibitor synthesis.
- The patent’s enforceability depends on established process infringement and alternative synthesis pathways.
- Future challenges may include developing alternative methods or patent expiration due to patent term.
Frequently Asked Questions
1. Can other companies synthesize the same compound using different methods without infringing this patent?
Yes, if they employ different synthetic routes that do not utilize the specific reagents or conditions claimed.
2. Does this patent cover the therapeutic use of the kinase inhibitor?
No, it covers the manufacturing process, not the compound's use or formulation.
3. What is the patent’s potential expiration date?
Expected around August 2026, considering the patent term and adjustments.
4. Are there similar patents in Europe or internationally?
Yes, related applications exist in Europe (EP 2,400,123) and WO filings, covering similar processes.
5. Has this patent faced any legal challenges?
No publicly known legal challenges exist as of now.
References
- United States Patent and Trademark Office. Patent No. 7,959,566. (2014).
- European Patent Office. Patent application EP 2,400,123.
- World Intellectual Property Organization. WO 2009/021456.
- USPTO Patent Full-Text and Image Database. (2023).
